CoChat

Human Hepatocytes as a Tool for Studying Toxicity and Drug Metabolism

Gomez-Lechon, M., Donato, M., Castell, J., Jover, R. · 2003 · Current Drug Metabolism

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Drugs are usually biotransformed into new chemical species that may have either toxic or therapeutic effects. Drug metabolism studies are routinely performed in laboratory animals but, due to metabolic interspecies differences when compared to man, they are not accurate enough to anticipate the metabolic profile of a drug in humans. Human hepatocytes in primary culture provide the closest in vitro model to human liver and the only model that can produce a metabolic profile of a given drug that is very similar to that found in vivo. However their availability is limited due to the restricted access to suitable tissue samples. The scarcity of human liver has led to optimising the cryopreservation of adult hepatocytes for long-term storage and regular supply. Human hepatocytes in primary culture express typical hepatic functions and express drug metabolising enzymes. Moreover, qualitative and quantitative similarities between in vitro and in vivo metabolism of drugs were observed. Different strategies have been envisaged to prolong cell survival and delay the spontaneous decay of the differentiated phenotype during culture. Thus, hepatocytes represent the most appropriate model for the evaluation of integrated drug metabolism, toxicity/metabolism correlations, mechanisms of hepatotoxicity, and the interactions (inhibition and induction) of xenobiotics and drug-metabolising enzymes. However, in view of limitations of primary hepatocytes, efforts are made to develop alternative cellular models (i.e. metabolic competent CYP-engineered cells stably expressing individual CYPs and transient expression of CYPs by transduction of hepatoma cells with recombinant adenoviruses). In summary, several cellular tools are available to address key issues at the earliest stages of drug development for a better candidate selection and hepatotoxicity risk assessment.

Overview

Integrity signals

Registry

Crossref · 10.2174/1389200033489424

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 272

Metadata

Authors
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R.
Affiliations
Hospital Universitari i Politècnic La Fe (ES)
Venue
Current Drug Metabolism
Published
2003-08-01
Volume
4
Issue
4
Pages
292-312
ISSN
1389-2002 (ISSN-L)
OpenAlex
W2112247582
Cited by
242
References
2
Citations by year
2026: 8 · 2025: 11 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 18 · 2020: 6 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 14 · 2014: 9 · 2013: 16 · 2012: 12
FWCI
7.47
Type
journal article
Language
en
Open access
closed
Locations
  • Current Drug Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
human hepatocytes, primary hepatocyte culture, drug metabolism, hepatotoxicity, toxicity prediction, drug-metabolizing enzymes, adenoviral transduction, hepatoma cells, xenobiotic interactions, in vitro-in vivo correlation, drug development
MeSH terms
Cells, Cultured, Cytochrome P-450 Enzyme System, Drug Interactions, Pharmaceutical Preparations, Humans, Liver, Models, Biological, Time Factors, Hepatocytes, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.